Webinar

Spatial Biology: the new dimension to breakthrough research

The Spatial Biology Week™️

Watch on demand

ONLINE

FREE REGISTRATION

WATCH ON-DEMAND

Spatial Biology: the new dimension to breakthrough research

Multiple clinical trials have shown an overall improved response rate in cancers by combining radiotherapy (RT) with immunotherapy (IO), however, treatment rates remain low and unpredictable. The suboptimal outcomes are largely due to the lack of knowledge of the underlying immunomodulation effect and an effective treatment-response biomarker. Previous studies using tissue-based assays like multiplexed immunofluorescence (mIF) have demonstrated that cellular spatial organization within the tumor microenvironment represents a critical factor influencing anti-tumor immunity. Hence, we sought to characterize the in-situ molecular immune response of RT-treated cancer tissues by using multiple spatial and immunology technologies, to advance our understanding of RT-induced immunomodulation effect and its synergistic benefits with IO.

Speaker

Joe Yeong, MBBS, PhD, Mmed (Pathology)

Joe Yeong, MBBS, PhD, Mmed (Pathology)

Group Leader

Institute of Molecular and Cell Biology, A*STAR, Singapore | Department of Anatomical Pathology, Singapore General Hospital

Dr. Joe Yeong’s main research focus is to understand and overcome the resistance of immunecheckpoint blockade immunotherapy. As an immuno-pathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is the pioneer in automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantitate tumour immune microenvironment in clinical samples, and has published > 100 papers in this field. His works on cancer immunology are included in multiple National Medical Research Council funded studies as well as pharmaceutical industry sponsored projects (>13 million dollars since 2017). He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium as well as multiplex IF expert consensus meeting 2022. He also serves as Program Chair of one of the largest AI medical Imaging conferences, CLINICCAI-MICCAI. He is also a board member of Elsevier (Immunoinformatics), SLAS Technology (Journal), Frontiers and Pathogens. He serves as a Secretary (Executive) in Singapore Society of Oncology – Cancer Immunotherapy Consortium, Co-lead in Education/Diagnostic of Singhealth Duke-NUS Cell Therapy Centre as well as Advisor (Spatial Technology), Cancer Discovery Hub, National Cancer Centre.

Speaker

Carlo Bifulco, MD

Carlo Bifulco, MD

Member and Director, Translational Molecular Pathology and Molecular Genomics

Earle A. Chiles Research Institute, Providence

Dr. Bifulco is a Surgical Pathologist with additional fellowship subspecialty training, expertise, and board certification in Molecular Genetic Pathology and Hematopathology. Dr. Bifulco currently serves as Chief Medical Officer, Providence Genomics, and as Member and Director of Translational Molecular Pathology and Molecular Genomics at the Earle A. Chiles Research Institute in Portland, Oregon, a division of Providence Cancer Institute. He oversees Providence Molecular Genomics Laboratory, one of the largest clinical genomics labs in the Pacific Northwest, which provides state-of-the-art genomic sequencing to cancer patients across the seven state PSJH system.

 

Prior to joining Providence, Dr. Bifulco served on the Pathology faculty at Yale University and completed fellowships in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center. His current translational research is focused on supporting the characterization of the tumor immune microenvironment through immunohistochemical and image analysis techniques, and on the integration of genomics with immunotherapies. Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC), and is Co-Chair of the SITC Pathology Task Force convened to establish multiplexed immunohistochemistry/ immunofluorescence (mIHC/IF) standards.

Dissertation points:

  • Desired features of spatial biology technologies
  • Relationship between tissue biomarkers and liquid biopsies in oncology
  • The next in the quest to understand cancer tissue microenvironment dynamics

Speakers

Joe Yeong, MBBS, PhD, Mmed (Pathology)

Joe Yeong, MBBS, PhD, Mmed (Pathology)

Group Leader

Institute of Molecular and Cell Biology, A*STAR, Singapore | Department of Anatomical Pathology, Singapore General Hospital

Dr. Joe Yeong’s main research focus is to understand and overcome the resistance of immunecheckpoint blockade immunotherapy. As an immuno-pathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is the pioneer in automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantitate tumour immune microenvironment in clinical samples, and has published > 100 papers in this field. His works on cancer immunology are included in multiple National Medical Research Council funded studies as well as pharmaceutical industry sponsored projects (>13 million dollars since 2017). He also served as a committee member in the World Immunotherapy Council, Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium as well as multiplex IF expert consensus meeting 2022. He also serves as Program Chair of one of the largest AI medical Imaging conferences, CLINICCAI-MICCAI. He is also a board member of Elsevier (Immunoinformatics), SLAS Technology (Journal), Frontiers and Pathogens. He serves as a Secretary (Executive) in Singapore Society of Oncology – Cancer Immunotherapy Consortium, Co-lead in Education/Diagnostic of Singhealth Duke-NUS Cell Therapy Centre as well as Advisor (Spatial Technology), Cancer Discovery Hub, National Cancer Centre.

Carlo Bifulco, MD

Carlo Bifulco, MD

Member and Director, Translational Molecular Pathology and Molecular Genomics

Earle A. Chiles Research Institute, Providence

Dr. Bifulco is a Surgical Pathologist with additional fellowship subspecialty training, expertise, and board certification in Molecular Genetic Pathology and Hematopathology. Dr. Bifulco currently serves as Chief Medical Officer, Providence Genomics, and as Member and Director of Translational Molecular Pathology and Molecular Genomics at the Earle A. Chiles Research Institute in Portland, Oregon, a division of Providence Cancer Institute. He oversees Providence Molecular Genomics Laboratory, one of the largest clinical genomics labs in the Pacific Northwest, which provides state-of-the-art genomic sequencing to cancer patients across the seven state PSJH system.

 

Prior to joining Providence, Dr. Bifulco served on the Pathology faculty at Yale University and completed fellowships in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center. His current translational research is focused on supporting the characterization of the tumor immune microenvironment through immunohistochemical and image analysis techniques, and on the integration of genomics with immunotherapies. Dr. Bifulco serves on the Global Colon Cancer Immunoscore Task Force led by the Society for Immunotherapy of Cancer (SITC), and is Co-Chair of the SITC Pathology Task Force convened to establish multiplexed immunohistochemistry/ immunofluorescence (mIHC/IF) standards.

Related Events